VYNE Therapeutics Inc (VYNE) USD0.0001
Sell:$1.39Buy:$1.47
$0.45
(23.94%)
- This stock can be held in a
Stocks and Shares ISA$0.45
(23.94%)$0.45
(23.94%)Company Information
About this company
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Key people
Key facts
- EPICVYNE
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS92941V3087
- Market cap$27.99m
- Employees13
- Shares in issue15.21m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.